Biocryst Pharmaceuticals
Presence
Biocryst Pharmaceuticals is one of the...
Biocryst Pharmaceuticals is a company listed under the stock ticker BCRX (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Biocryst Pharmaceuticals
- Jon Stonehouse, President, Chief Executive Officer, Director
- Amy McKee, Director
- George Abercrombie, Director
Popular executive movements at Biocryst Pharmaceuticals
- Kenneth Lee, Director, will leave the company on Dec. 31, 2023 (posted on December 4 2023).
Create your alert
to follow the executive moves at Biocryst Pharmaceuticals.
Biotechnology
Biocryst Pharmaceuticals has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Biocryst Pharmaceuticals
- BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones | BioCryst Pharmaceuticals
- BioCryst Resumes Enrollment in BCX9930 Clinical Program | BioCryst Pharmaceuticals
- BioCryst Resumes Enrollment in BCX9930 Clinical Program | BioCryst Pharmaceuticals
- BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones | BioCryst Pharmaceuticals
- BioCryst to Report Second Quarter 2022 Financial Results on August 4 | BioCryst Pharmaceuticals
- BioCryst to Report Second Quarter 2022 Financial Results on August 4 | BioCryst Pharmaceuticals
- BioCryst to Present at Upcoming Investor Conference | BioCryst Pharmaceuticals
- BioCryst to Present at Upcoming Investor Conference | BioCryst Pharmaceuticals
- BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) | BioCryst Pharmaceuticals
- BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) | BioCryst Pharmaceuticals
- View more press releases Close
Social media about Biocryst Pharmaceuticals
- Biocryst Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Biocryst Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Jon Stonehouse 
Call Biocryst Pharmaceuticals at +1 919...
